Markets:

Overview

News

Currencies

International

Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

15.09 +0.91 (+6.42%)

Streaming Delayed Price Updated: 3:33 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Earnings Scheduled For March 13, 2025 ↗

March 13, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts ↗

February 11, 2025

Via Benzinga

Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗

January 15, 2025

Via Benzinga

Where Regenxbio Stands With Analysts ↗

December 11, 2024

Via Benzinga

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns ↗

February 11, 2025

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 14, 2025

Via Benzinga

Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗

January 14, 2025

Via Benzinga

Workday, Apollo Global To Join S&P 500 Index In Quarterly Balance ↗

December 06, 2024

They'll join the index before the open on Dec. 23 as part of a quarterly rebalance.

Via Investor's Business Daily

Topics Stocks

5 Analysts Have This To Say About Regenxbio ↗

November 15, 2024

Via Benzinga

What 4 Analyst Ratings Have To Say About Regenxbio ↗

October 10, 2024

Via Benzinga

Assessing Regenxbio: Insights From 5 Financial Analysts ↗

September 04, 2024

Via Benzinga

What's Going On With REGENXBIO Shares Monday? ↗

November 18, 2024

REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.

Via Benzinga

Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday ↗

November 18, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 06, 2024

Via Benzinga

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Where Regenxbio Stands With Analysts ↗

August 05, 2024

Via Benzinga

Assessing Regenxbio: Insights From 4 Financial Analysts ↗

June 07, 2024

Via Benzinga

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

From FN Media Group LLC

Via GlobeNewswire

7 Biotech Stocks to Buy for Their Game-Changing Potential ↗

August 08, 2024

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

Via InvestorPlace

Why Is Clearside Biomedical Stock Gaining Today? ↗

June 25, 2024

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS...

Via Benzinga

Evaluating Regenxbio: Insights From 9 Financial Analysts ↗

May 15, 2024

Via Benzinga

Where Regenxbio Stands With Analysts ↗

April 12, 2024

Via Benzinga

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy ↗

June 21, 2024

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.

Via Benzinga

Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy ↗

June 20, 2024

The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease.

Via Investor's Business Daily

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test ↗

June 13, 2024

Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom.

Via Investor's Business Daily

Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗

June 07, 2024

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

Via Benzinga

RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

RGNX stock results show that Regenxbio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 25, 2024

Via Benzinga

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? ↗

March 13, 2024

The threat is still emerging, but it could be significant.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.